IP Verse

Aquestive Therapeutics, Inc. vs Iono Pharma, LLC

The detailed information for PTAB case with proceeding number IPR2025-00874 filed by Aquestive Therapeutics, Inc. against Iono Pharma, LLC on May 16, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2025-00874
Filing Date: May 16, 2025
Petitioner: Aquestive Therapeutics, Inc.
Respondent: Iono Pharma, LLC
Status: Pending
Respondent Application Number: 16347625
Respondent Tech Center: 1600
Respondent Patent Number: 11021437

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
EXPUNGED	Jun 18, 2025	PAPER	BOARD
Notice: Notice filing date accorded	Jun 18, 2025	PAPER	BOARD
Notice: Patent Owner's Mandatory Notice	Jun 18, 2025	PAPER	PATENT OWNER
Notice: Patent Owner's Power of Attorney	Jun 18, 2025	PAPER	PATENT OWNER
Almoazen '437 Patent, U.S. Patent No. 11,021,437 B2.	May 16, 2025	EXHIBIT	PETITIONER
Truelove 1, U.S. Patent No. 3,809,714	May 16, 2025	EXHIBIT	PETITIONER
Ashraf, “Considerations in Developing Sublingual Tablets – An Overview"	May 16, 2025	EXHIBIT	PETITIONER
Fuchs, U.S. Patent No. 4,136,145.	May 16, 2025	EXHIBIT	PETITIONER
Almoazen '437 Patent File History, U.S. App. Ser. No. 16/347,625.	May 16, 2025	EXHIBIT	PETITIONER
Truelove 2, U.S. Patent No. 3,825,583.	May 16, 2025	EXHIBIT	PETITIONER
Truelove 4, “Prodrug Approaches to , , , Novel Epinephrine Prodrug”	May 16, 2025	EXHIBIT	PETITIONER
Truelove 3, U.S. Patent No. 3,868,461.	May 16, 2025	EXHIBIT	PETITIONER
The Merck Index, 12th Ed., 1996, p. 613.	May 16, 2025	EXHIBIT	PETITIONER
USP certificate for epinephrine, dated 14 Aug 2017.	May 16, 2025	EXHIBIT	PETITIONER
EpiPen Information	May 16, 2025	EXHIBIT	PETITIONER
Almoazen ‘437 Patent Provisional Application, Ser. No. 62,421,316.	May 16, 2025	EXHIBIT	PETITIONER
Almoazen PCT Application, WO2018/089570 A1 (PCT/US2017/060761).	May 16, 2025	EXHIBIT	PETITIONER
Florence, “Physicochemical Principles of Pharmacy”.	May 16, 2025	EXHIBIT	PETITIONER
Bodor, U.S. Patent No. 4,145,441.	May 16, 2025	EXHIBIT	PETITIONER
Rawas-Qalaji, U.S. Patent Application Publication No. US 2007/0202163 A1.	May 16, 2025	EXHIBIT	PETITIONER
Ettmayer, “Lessons Learned from Marketed and Investigational Prodrug".	May 16, 2025	EXHIBIT	PETITIONER
Rautio, “Prodrugs: design and clinical applications”.	May 16, 2025	EXHIBIT	PETITIONER
Silverman, “Prodrugs and drug delivery systems”.	May 16, 2025	EXHIBIT	PETITIONER
Schobel, U.S. Patent No. 11,191,737 B2.	May 16, 2025	EXHIBIT	PETITIONER
Almoazen Paper, “Development of a fast dissolving film of epinephrine ...".	May 16, 2025	EXHIBIT	PETITIONER
Baldessarini, “Hydrolysis of diester prodrugs of apomorphine”.	May 16, 2025	EXHIBIT	PETITIONER
Kristoffersson, “Drug latentiation of terbutaline”.	May 16, 2025	EXHIBIT	PETITIONER
Christrup, “Improvement of buccal delivery ... using the prodrug approach”	May 16, 2025	EXHIBIT	PETITIONER
Lieberman, “The diagnosis and management of anaphylaxis practice parameter"	May 16, 2025	EXHIBIT	PETITIONER
den Daas, “Improvement of the oral bioavailability . . . ester prodrugs".	May 16, 2025	EXHIBIT	PETITIONER
Hansen 1991, “Ketobemidone prodrugs for buccal delivery”.	May 16, 2025	EXHIBIT	PETITIONER
Hansen 1992, “Ketobemidone prodrugs for buccal delivery ...".	May 16, 2025	EXHIBIT	PETITIONER
Markup of EX1001 showing EX1022 contribution.	May 16, 2025	EXHIBIT	PETITIONER
Roche, “Design of biopharmaceutical properties through prodrugs ...".	May 16, 2025	EXHIBIT	PETITIONER
Markup of EX1022 showing material found in EX1001.	May 16, 2025	EXHIBIT	PETITIONER
Morrison and Boyd, “Organic Chemistry”, Sections 18.1-18-4.	May 16, 2025	EXHIBIT	PETITIONER
Streitwieser, “Introduction to Organic Chemistry”, excerpts.	May 16, 2025	EXHIBIT	PETITIONER
Stepensky, “Long-Term Stability Study of L-Adrenaline Injections ...".	May 16, 2025	EXHIBIT	PETITIONER
Rautio II, “Prodrugs—from Serendipity to Rational Design”.	May 16, 2025	EXHIBIT	PETITIONER
Senel, “Drug permeation enhancement via buccal route ...".	May 16, 2025	EXHIBIT	PETITIONER
Kohn, “Clinical Comparison of Dipivalyl Epinephrine and Epinephrine ...".	May 16, 2025	EXHIBIT	PETITIONER
Journal of Medicinal Chemistry (JMC) Manuscript Requirements	May 16, 2025	EXHIBIT	PETITIONER
Declaration of Jarkko Rautio, Ph.D.	May 16, 2025	EXHIBIT	PETITIONER
Declaration of Nicholas A. Meanwell, Ph.D.	May 16, 2025	EXHIBIT	PETITIONER
Notice: Power of Attorney	May 16, 2025	PAPER	PETITIONER
Petition: as filed	May 16, 2025	PAPER	PETITIONER